Anto Biosciences

Executive Summary

Anto Biosciences is a San Diego-based, Y Combinator-backed microbiome therapeutics company developing live biotherapeutic products (LBPs) and microbiome-derived molecules for immune and metabolic disorders. Founded in 2024, the company employs a proprietary platform to identify and engineer specific bacterial strains that modulate host physiology, aiming to create a new class of targeted living medicines. Currently in Phase 1 development, Anto addresses high unmet needs in gastroenterology, immunology, and metabolic diseases. Its early-stage pipeline and novel approach position it as a potential pioneer in the microbiome space, though it has not disclosed total funding or valuation. The company's success hinges on advancing its lead candidate through clinical trials and establishing strategic partnerships to validate its platform.

Upcoming Catalysts (preview)

• Q3 2026Initiation of Phase 1 clinical trial for lead LBP candidate70% success
• H2 2026Announcement of strategic partnership or licensing deal with a major pharma50% success
• Q2 2026Publication of preclinical proof-of-concept data in a peer-reviewed journal80% success